{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:26:25Z","timestamp":1778718385063,"version":"3.51.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":3249,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1111\/ajt.12518","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T11:06:42Z","timestamp":1385464002000},"page":"115-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Efficacy and Safety of Vildagliptin in New-Onset Diabetes After Kidney Transplantation\u2014A Randomized, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1016","volume":"14","author":[{"given":"M.","family":"Haidinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Werzowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hecking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Antlanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Stemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pleiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"D\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pacini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.12518_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrneph.2011.174","article-title":"Complications associated with new-onset diabetes after kidney transplantation","volume":"8","author":"Sharif","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1111\/ajt.12518_bib2","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00125-011-2105-9","article-title":"The association of early post-transplant glucose levels with long-term mortality","volume":"54","author":"Valderhaug","year":"2011","journal-title":"Diabetologia"},{"key":"10.1111\/ajt.12518_bib3","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2215\/CJN.09481209","article-title":"Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus","volume":"5","author":"Chakkera","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/ajt.12518_bib4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/01.tp.0000259617.21741.95","article-title":"Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients","volume":"83","author":"Burroughs","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12518_bib5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/ndt\/gfs583","article-title":"Novel views on new-onset diabetes after transplantation: Development, prevention and treatment","volume":"28","author":"Hecking","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ajt.12518_bib6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2337\/diacare.27.3.805","article-title":"New-onset diabetes after transplantation 2003 International Consensus Guidelines: An endocrinologist\u2019s view","volume":"27","author":"Davidson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/ajt.12518_bib7","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc12-2441","article-title":"Glucose metabolism after renal transplantation","volume":"36","author":"Hecking","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/ajt.12518_bib8","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/dc12-1894","article-title":"Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation","volume":"36","author":"Zelle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/ajt.12518_bib9","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/TP.0b013e318260b1e9","article-title":"Clinical trials for treatment of NODAT: Time to collaborate","volume":"94","author":"Sharif","year":"2012","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12518_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation","volume":"23","author":"Hecking","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/ajt.12518_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/TP.0b013e318276a20e","article-title":"Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: A randomized, placebo-controlled clinical trial","volume":"95","author":"Werzowa","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12518_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/qjmed\/hct016","article-title":"Metformin for patients with diabetes and concomitant renal restrictions-is there an evidence base?","volume":"106","author":"Sharif","year":"2013","journal-title":"QJM"},{"key":"10.1111\/ajt.12518_bib13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1634\/theoncologist.2012-0302","article-title":"Cancer risk for patients using thiazolidinediones for type 2 diabetes: A meta-analysis","volume":"18","author":"Bosetti","year":"2013","journal-title":"Oncologist"},{"key":"10.1111\/ajt.12518_bib14","doi-asserted-by":"crossref","first-page":"E675","DOI":"10.1503\/cmaj.112102","article-title":"Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis","volume":"184","author":"Colmers","year":"2012","journal-title":"CMAJ"},{"key":"10.1111\/ajt.12518_bib15","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study","volume":"26","author":"Delea","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/ajt.12518_bib16","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1345\/aph.1K286","article-title":"Effects of thiazolidinediones on bone loss and fracture","volume":"41","author":"Murphy","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1111\/ajt.12518_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00508-010-1369-2","article-title":"Thiazolidinediones in the treatment of patients with post-transplant-hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT)\u2014A new therapeutic option?","volume":"122","author":"Saemann","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"10.1111\/ajt.12518_bib18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1089\/dia.2012.0144","article-title":"The duration of sulfonylurea treatment is associated with beta-cell dysfunction in patients with type 2 diabetes mellitus","volume":"14","author":"Shin","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"10.1111\/ajt.12518_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1210\/jc.2004-0699","article-title":"Sulfonylurea induced beta-cell apoptosis in cultured human islets","volume":"90","author":"Maedler","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/ajt.12518_bib20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0272-6386(00)70204-6","article-title":"Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease","volume":"35","author":"Krepinsky","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/ajt.12518_bib21","first-page":"CD006739","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus","author":"Richter","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/ajt.12518_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"beta-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1111\/ajt.12518_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.arcmed.2013.03.004","article-title":"Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats","volume":"44","author":"\u00c1vila Dde","year":"2013","journal-title":"Arch Med Res"},{"key":"10.1111\/ajt.12518_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1530\/JOE-11-0479","article-title":"The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice","volume":"214","author":"Jelsing","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1111\/ajt.12518_bib25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1463-1326.2012.01619.x","article-title":"Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic beta-cell mass in a streptozotocin-induced mouse model of type 2 diabetes","volume":"14","author":"Poucher","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ajt.12518_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00125-011-2365-4","article-title":"Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice","volume":"55","author":"Takeda","year":"2012","journal-title":"Diabetologia"},{"key":"10.1111\/ajt.12518_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrcardio.2012.183","article-title":"Cardiovascular effects of gliptins","volume":"10","author":"Scheen","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1111\/ajt.12518_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"10.1111\/ajt.12518_bib29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2337\/dc09-1867","article-title":"Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy","volume":"33","author":"Ahren","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1111\/ajt.12518_bib30","first-page":"61","article-title":"Exenatide improves glucocorticoid-induced glucose intolerance in mice","volume":"4","author":"Zhao","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1111\/ajt.12518_bib31","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/db05-1220","article-title":"Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4","volume":"55","author":"Ranta","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/ajt.12518_bib32","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0028-1082334","article-title":"Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: Comparison with metformin","volume":"40","author":"Goke","year":"2008","journal-title":"Horm Metab Res"},{"key":"10.1111\/ajt.12518_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.diabres.2006.12.009","article-title":"Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes","volume":"76","author":"Pi-Sunyer","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1111\/ajt.12518_bib34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ncpendmet0552","article-title":"Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?","volume":"3","author":"Retnakaran","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"159","key":"10.1111\/ajt.12518_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1742-1241.2007.01692.x","article-title":"Vildagliptin: Clinical trials programme in monotherapy and combination therapy for type 2 diabetes","author":"Rosenstock","year":"2008","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1111\/ajt.12518_bib36","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc12-1365","article-title":"Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency","volume":"36","author":"Arjona Ferreira","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/ajt.12518_bib37","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1463-1326.2011.01467.x","article-title":"Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial","volume":"13","author":"Lukashevich","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ajt.12518_bib38","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1463-1326.2012.01634.x","article-title":"One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment","volume":"14","author":"Kothny","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ajt.12518_bib39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1507\/endocrj.EJ11-0025","article-title":"The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis","volume":"58","author":"Ito","year":"2011","journal-title":"Endocr J"},{"key":"10.1111\/ajt.12518_bib40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.metabol.2007.10.017","article-title":"Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias Study","volume":"57","author":"Valdes","year":"2008","journal-title":"Metabolism"},{"key":"10.1111\/ajt.12518_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1745-6215-11-91","article-title":"A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation","volume":"11","author":"Haidinger","year":"2010","journal-title":"Trials"},{"issue":"Suppl 1","key":"10.1111\/ajt.12518_bib42","first-page":"S61","article-title":"Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association","volume":"31","author":"Bantle","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1111\/ajt.12518_bib43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1521-690X(03)00042-3","article-title":"Methods for clinical assessment of insulin sensitivity and beta-cell function","volume":"17","author":"Pacini","year":"2003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1111\/ajt.12518_bib44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-2007-991172","article-title":"Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes","volume":"39","author":"Ahren","year":"2007","journal-title":"Horm Metab Res"},{"key":"10.1111\/ajt.12518_bib45","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/TP.0b013e3182a012f3","article-title":"Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin","volume":"96","author":"Yates","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12518_bib46","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/dom.12005","article-title":"Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes","volume":"15","author":"Hamamoto","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/ajt.12518_bib47","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s00125-013-2927-8","article-title":"Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model","volume":"56","author":"Omar","year":"2013","journal-title":"Diabetologia"},{"key":"10.1111\/ajt.12518_bib48","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/TP.0b013e3182347ea4","article-title":"Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation","volume":"92","author":"Lane","year":"2011","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12518_bib49","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2174\/157488611798918700","article-title":"Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes","volume":"6","author":"Mikhail","year":"2011","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ajt.12518_bib50","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/j.ijcard.2013.04.121","article-title":"Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction","volume":"168","author":"Theiss","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1111\/ajt.12518_bib51","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1111\/ajt.12518_bib52","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler","year":"2013","journal-title":"Diabetes"},{"key":"10.1111\/ajt.12518_bib53","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-0599","article-title":"The safety of incretin-based therapies\u2014review of the scientific evidence","volume":"96","author":"Drucker","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/ajt.12518_bib54","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/TP.0b013e31827a3d3e","article-title":"Exercise training in solid organ transplant recipients: A systematic review and meta-analysis","volume":"95","author":"Didsbury","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12518_bib55","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1399-0012.2009.01098.x","article-title":"Physical training effects in renal transplant recipients","volume":"24","author":"Romano","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1111\/ajt.12518_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/TP.0b013e3181605ebf","article-title":"Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia","volume":"85","author":"Sharif","year":"2008","journal-title":"Transplantation"},{"key":"10.1111\/ajt.12518_bib57","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/01.tp.0000250924.99855.42","article-title":"The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon","volume":"82","author":"Sharif","year":"2006","journal-title":"Transplantation"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.12518","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522253027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522253027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:02:04Z","timestamp":1761627724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522253027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1600613522253027"],"URL":"https:\/\/doi.org\/10.1111\/ajt.12518","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Vildagliptin in New-Onset Diabetes After Kidney Transplantation\u2014A Randomized, Double-Blind, Placebo-Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.12518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}